Pinealon
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
What is it?
Pinealon is a synthetic Khavinson tripeptide: sequence Glu-Asp-Arg (EDR). Molecular formula C₁₅H₂₆N₆O₈, molecular weight 418.40 g/mol. Developed by the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology as part of the broader Khavinson peptide-bioregulator program.
The Khavinson framework, in brief. Pinealon is one of roughly 15 organ-targeted peptides from a 1970s Soviet military-medicine research program at the Military Medical Academy in Leningrad. Researchers extracted tissue-specific peptide fractions from organs (thymus, pineal, cortex, etc.) and observed bioactive effects when re-administered. Vladimir Khavinson became the program’s central figure; the post-1991 St. Petersburg Institute of Bioregulation and Gerontology became its institutional home. The theoretical claim: short peptides (2-4 amino acids) cross cell + nuclear membranes → bind specific DNA promoter regions → modulate transcription in a tissue-specific way, with each peptide’s sequence claimed to reproduce a fragment originally extracted from its target organ tissue. Western reception is split: the conventional Western position is preclinical-only, single-research-group, weak methodology, mechanism heterodox; the Russian/Eastern European position is a 50-year sustained research program with consistent reported outcomes and several sibling peptides (Cortexin, Thymalin) approved for clinical use in Russia. OHM’s lean: report both perspectives honestly — don’t dismiss the body of work, don’t overclaim it. The mechanism is interesting; the lack of Western RCT replication is a real evidence gap; both are true.
The name myth — Pinealon is NOT from the pineal gland. One of the most-repeated false claims about Pinealon in the peptide community is that it’s extracted from the pineal gland and acts as a “pineal regulator” because of the name. It isn’t. Pinealon is a synthetic tripeptide discovered during the molecular analysis of cortexin — a brain-cortex extract, not a pineal extract. Its documented effects center on brain cortex + hippocampus, mitochondrial function, and gene-expression modulation. One vendor-source’s own mass-spectrometry analysis of pineal-gland peptide extracts reportedly found zero Pinealon present in the pineal gland tissue itself. Even within the Khavinson framework’s own tissue-specificity logic, Pinealon’s tissue origin is cortical, not pineal — the “Pinealon = pineal regulator” framing is a vendor/community misconception that should be retired.
What does it do in my body?
A triple-mechanism case (Khavinson framework):
- PEPT2 oral transport — Pinealon is small enough to cross intestinal, renal, and brain membranes via the PEPT2 peptide transporter. Genuinely orally bioavailable — rare for a peptide and one of Pinealon’s distinguishing features bioavailability magnitude.
- DNA regulatory binding — the Khavinson core claim. Pinealon is said to directly bind DNA promoter regions in neuronal nuclei and modulate gene expression. Mechanism is heterodox by Western molecular-biology standards and under-replicated outside the Khavinson group independent replication.
- Antioxidant + serotonergic modulation — measured oxidative-stress reduction and serotonin-pathway stimulation in brain cortex in animal models.
The FKBP1B “master regulator” hypothesis — what’s actually in the primary literature
Some peptide-community sources frame Pinealon as the only compound ever shown to “activate the master regulator of brain aging” — a gene called FKBP1B — citing a result where 872 of 876 hippocampal genes reversed direction in a brain-aging model. The underlying literature does not say what that framing implies. Two separate papers are being stitched together:
- Khavinson, Linkova, Tarnovskaya 2019 Molecular Biology (PMID 31099784) — proposes that EDR (Pinealon) binds histone H1.3 and may alter chromatin at the Fkbp1b locus, thereby activating its transcription. This is a molecular-docking + literature-synthesis paper. It does NOT report Pinealon administration to animals producing hippocampal Fkbp1b upregulation.
- Gant, Blalock, Chen, Kadish et al. 2018 J Neurosci (PMID 29255009) — delivered FKBP1b via AAV2/9 viral vector directly into aged F344 rat hippocampus. Of 876 aging-shifted, FKBP1b-sensitive genes, 872 reversed direction — Y-maze cognition also improved. Pinealon was never used in this study; the gene was delivered by viral vector.
The honest read: Pinealon-driven FKBP1B upregulation reversing 872 hippocampal genes has not been demonstrated in a single experiment. The proposed mechanism (Pinealon → histone H1.3 → Fkbp1b transcription) is plausible chromatin biology from the Khavinson group; the viral-vector validation that FKBP1b restoration can reverse hippocampal aging-gene patterns is independently real (Gant 2018, University of Kentucky). The bridge between them is the active question. Treat “Pinealon activates the master regulator and reverses 872 genes” as community marketing extrapolation, not a single-paper finding.
How can it help me?
- Where the science stands: Entirely Khavinson-group + collaborators; no Western RCTs; sustained decade-plus publication record
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
- Mild and uncommon: Headache (early days), sleep disturbance with evening dosing (dose AM only), mild GI upset on the oral route, injection-site reactions.
- No serious AEs reported in published Russian research across a decade+ — but this is Russian-source pharmacovigilance only; long-term Western safety data doesn’t exist.
- Contraindications cited in the Russian protocols: Pregnancy, breastfeeding, age <18, active seizure disorders, concurrent serotonergic medications (SSRIs, etc.).
- Counterfeiting risk is significant for this category specifically — a verified-COA vendor matters more for Khavinson-family peptides than for most others because Russian-source counterfeit product is the dominant gray-market failure mode.
Regulatory status: Not FDA-approved. Long clinical-use history in Russia under Khavinson-school protocols; no Western RCTs.
Where to buy. Pinealon is not in Alyve’s current launch catalog, but it is available through BioLongevity — use code OHM-15 (BioLongevity shares Alyve’s coupon code) for 15% off. Given the counterfeiting risk flagged above, a third-party-COA, identity-confirmed product matters disproportionately for this peptide.
Typical dosing
Talk to your medical provider before starting any protocol. That said, here are the doses most people commonly use — shared for educational purposes so you can have an informed conversation. These peptides are sold for research use only and are not FDA-approved drugs, and this isn't medical advice.
Both oral and injectable are validated within the Khavinson protocols — Pinealon’s oral viability is genuinely unusual for a peptide and is one of its main practical features.
| Route | Dose | Cycle | Frequency |
|---|---|---|---|
| Oral | 20 mg/day (typically 2× 10 mg capsules), morning, empty stomach | 20-30 consecutive days | 2-3 cycles/year |
| Subcutaneous | 5-10 mg/day; rotate injection sites | 10-20 consecutive days | 2-3 cycles/year |
Dosing-source discrepancy to flag. A separate practitioner camp running Pinealon clinically describes the standard starting dose as ~200 mcg/day = 2 capsules of a 100-mcg formulation, with a brain-repair range up to ~900 mcg/day (9 capsules, divided 3×3), an injectable range of 0.01-0.1 mg/kg/day (the dose used in TBI patients per the Pinealon patent, ≈ 0.7-7 mg/day for a 70 kg adult), and an intranasal range matching the injectable. That’s two orders of magnitude below the 20 mg/day oral figure in the table above. The most likely reconciliation: the 20 mg figure tracks a different oral formulation (likely a higher-strength Russian retail capsule), while the 200-900 mcg figure tracks a lower-strength capsule format. OHM’s editorial position pending resolution: start at the low end of the lower range (~200 mcg/day) and titrate up only if needed, NOT default to the 20 mg figure — the lower starting dose is consistent with the dose range used in the published 5XFAD mouse study (400 μg/kg ≈ 28 mg for a 70 kg human, but injected IP not oral) and avoids the upper-range lethargy risk below. — the 100-mcg vs. 10-mg capsule formulation distinction needs pinning to a specific product.
Upper-range caveat: dosing near the upper end of the range (whichever scale you’re working in) can induce lethargy / drowsiness in some users. Stay in the lower-to-mid part of the range; only push toward the upper bound for a defined brain-repair use case with prior tolerance established.
Persistence claim: the Khavinson framework claims benefits continue 2-3 months post-cycle — the “epigenetic-like persistence” asserted for all Khavinson bioregulators (the basis for the cycle/rest pattern rather than continuous dosing) magnitude + duration in independent studies.
A surprising real-world signal — Pinealon for SLEEP (not its primary positioning)
Three independent practitioner-camp n=1 reports now converge on Pinealon improving sleep quality — none of them came from sources positioning Pinealon as a sleep compound, which strengthens the signal that it’s a real secondary effect rather than expectation bias.
- Humiston (2026-06-16, head-to-head self-test). A fitness creator tested three peptides head-to-head for sleep effects — DSIP (positioned as a sleep peptide; null for him), Epithalon (positioned partly on nocturnal-melatonin upregulation; null for him on sleep), and Pinealon (positioned as a neuroprotective antioxidant, not primarily as a sleep peptide). Pinealon was the surprise winner — he woke feeling almost rested despite a baseline of self-reported sleep apnea, light-sleeper sensitivity, and a noisy bedroom environment. The degraded baseline strengthens the signal.
- Norwitz (2026-06-24, oral Pinealon, second independent n=1). A Harvard-MD/Oxford-PhD-credentialed source, a self-described historically-poor sleeper, reported the most restorative sleep in a year+ after starting oral Pinealon, woke with notably elevated morning energy, and reported a distinctive REM-vivid dream phenomenon. Now uses Pinealon combined with Epitalon as a “Russian longevity stack” for circadian rhythm + brain function, with sleep remaining materially better since starting the combo.
- Huberman Lab / Koniver episode (2024-10-07, third independent n=1). On that podcast episode (segment ~01:24:47), Andrew Huberman reported that Pinealon (combined with oral glycine 3-5 g, pulsed not nightly) approximately doubled his self-tracked REM sleep over 4-6 months — from roughly 1-1.5 hours per night to roughly 3 hours per night — framing it as the first sleep tool he’d found that meaningfully moved REM sleep upward.
Honest framing: three n=1 anecdotes from three different credentialed sources are not a sleep trial — they do NOT establish Pinealon as a sleep peptide in any clinical-evidence sense. But the convergence pattern is worth weighing: all three users came at it from non-sleep-positioned contexts, baselines varied, and the mechanism plausibly supports the observation as a secondary effect (antioxidant + serotonergic-modulation → cortical calming + oxidative-stress reduction during sleep + dream-architecture changes consistent with REM expansion). The Huberman combination with oral glycine 3-5 g is a specific protocol detail worth knowing for anyone trialing the same approach. Cross-link to DSIP (the “intuitive” sleep peptide that didn’t help one tested user) and Epithalon (Norwitz pairs the two as a longevity stack).
What should I avoid combining — and what's synergistic?
Pinealon doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
How can I buy this?
Pinealon is available from BioLongevity Labs — use code OHM-15 at BioLongevity for 15% off. As always, buy only from a source that publishes third-party Certificates of Analysis (COAs) confirming identity and >99% purity.
When you use my coupon code to buy peptides with these sellers, you enjoy a discount off retail price, and I make a small commission which helps me to continue to offer this peptide educational site to you for free. I only have affiliate relationships with peptide manufacturers that show evidence that their peptides are 100% manufactured in the US, 3rd party lab tested for purity, transparent COAs posted on their websites, and that have good customer service.
A synthetic Khavinson-school tripeptide, genuinely orally bioavailable — rare for a peptide — with a sustained decade-plus Russian research record and a real (if unresolved) FKBP1B “brain-aging” mechanism story. Not from the pineal gland, despite the name.
| Class | Khavinson tripeptide (short-peptide bioregulator) |
| Sequence | Glu-Asp-Arg (EDR) |
| Mechanism (one line) | Claimed DNA-promoter binding + PEPT2-mediated oral transport + antioxidant/serotonergic modulation |
| Evidence base | Entirely Khavinson-group + collaborators; no Western RCTs; sustained decade-plus publication record |
| Safety record | No serious AEs reported in published Russian research; long-term Western safety data doesn’t exist; mild/uncommon side effects |
| Regulatory status | Not FDA-approved; significant counterfeiting risk in this category |
What it is
Pinealon is a synthetic Khavinson tripeptide: sequence Glu-Asp-Arg (EDR). Molecular formula C₁₅H₂₆N₆O₈, molecular weight 418.40 g/mol. Developed by the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology as part of the broader Khavinson peptide-bioregulator program.
The Khavinson framework, in brief. Pinealon is one of roughly 15 organ-targeted peptides from a 1970s Soviet military-medicine research program at the Military Medical Academy in Leningrad. Researchers extracted tissue-specific peptide fractions from organs (thymus, pineal, cortex, etc.) and observed bioactive effects when re-administered. Vladimir Khavinson became the program’s central figure; the post-1991 St. Petersburg Institute of Bioregulation and Gerontology became its institutional home. The theoretical claim: short peptides (2-4 amino acids) cross cell + nuclear membranes → bind specific DNA promoter regions → modulate transcription in a tissue-specific way, with each peptide’s sequence claimed to reproduce a fragment originally extracted from its target organ tissue. Western reception is split: the conventional Western position is preclinical-only, single-research-group, weak methodology, mechanism heterodox; the Russian/Eastern European position is a 50-year sustained research program with consistent reported outcomes and several sibling peptides (Cortexin, Thymalin) approved for clinical use in Russia. OHM’s lean: report both perspectives honestly — don’t dismiss the body of work, don’t overclaim it. The mechanism is interesting; the lack of Western RCT replication is a real evidence gap; both are true.
The name myth — Pinealon is NOT from the pineal gland. One of the most-repeated false claims about Pinealon in the peptide community is that it’s extracted from the pineal gland and acts as a “pineal regulator” because of the name. It isn’t. Pinealon is a synthetic tripeptide discovered during the molecular analysis of cortexin — a brain-cortex extract, not a pineal extract. Its documented effects center on brain cortex + hippocampus, mitochondrial function, and gene-expression modulation. One vendor-source’s own mass-spectrometry analysis of pineal-gland peptide extracts reportedly found zero Pinealon present in the pineal gland tissue itself. Even within the Khavinson framework’s own tissue-specificity logic, Pinealon’s tissue origin is cortical, not pineal — the “Pinealon = pineal regulator” framing is a vendor/community misconception that should be retired.
How it works
A triple-mechanism case (Khavinson framework):
- PEPT2 oral transport — Pinealon is small enough to cross intestinal, renal, and brain membranes via the PEPT2 peptide transporter. Genuinely orally bioavailable — rare for a peptide and one of Pinealon’s distinguishing features bioavailability magnitude.
- DNA regulatory binding — the Khavinson core claim. Pinealon is said to directly bind DNA promoter regions in neuronal nuclei and modulate gene expression. Mechanism is heterodox by Western molecular-biology standards and under-replicated outside the Khavinson group independent replication.
- Antioxidant + serotonergic modulation — measured oxidative-stress reduction and serotonin-pathway stimulation in brain cortex in animal models.
The FKBP1B “master regulator” hypothesis — what’s actually in the primary literature
Some peptide-community sources frame Pinealon as the only compound ever shown to “activate the master regulator of brain aging” — a gene called FKBP1B — citing a result where 872 of 876 hippocampal genes reversed direction in a brain-aging model. The underlying literature does not say what that framing implies. Two separate papers are being stitched together:
- Khavinson, Linkova, Tarnovskaya 2019 Molecular Biology (PMID 31099784) — proposes that EDR (Pinealon) binds histone H1.3 and may alter chromatin at the Fkbp1b locus, thereby activating its transcription. This is a molecular-docking + literature-synthesis paper. It does NOT report Pinealon administration to animals producing hippocampal Fkbp1b upregulation.
- Gant, Blalock, Chen, Kadish et al. 2018 J Neurosci (PMID 29255009) — delivered FKBP1b via AAV2/9 viral vector directly into aged F344 rat hippocampus. Of 876 aging-shifted, FKBP1b-sensitive genes, 872 reversed direction — Y-maze cognition also improved. Pinealon was never used in this study; the gene was delivered by viral vector.
The honest read: Pinealon-driven FKBP1B upregulation reversing 872 hippocampal genes has not been demonstrated in a single experiment. The proposed mechanism (Pinealon → histone H1.3 → Fkbp1b transcription) is plausible chromatin biology from the Khavinson group; the viral-vector validation that FKBP1b restoration can reverse hippocampal aging-gene patterns is independently real (Gant 2018, University of Kentucky). The bridge between them is the active question. Treat “Pinealon activates the master regulator and reverses 872 genes” as community marketing extrapolation, not a single-paper finding.
What the research shows
Entirely Khavinson-group + collaborators. No Western RCTs. The publication record is real and sustained over a decade-plus within the Russian ecosystem — that’s the honest both-sides framing.
- Khavinson et al. 2011 Rejuvenation Research 14(5) — cognitive support in offspring models.
- Arutjunyan et al. 2012 Int J Clin Exp Med 5(2) — prenatal neuroprotection.
- Khavinson et al. 2014 Bull Exp Biol Med 157(1) — cell renovation mechanisms.
- Karantysh et al. 2020 Neurochemical Journal 14(3) — learning + glutamatergic gene expression in diabetic aging models.
- Khavinson et al. 2020 Molecules — gene expression + protein synthesis regulation.
- Khavinson, Linkova, Tarnovskaya 2019 Molecular Biology (PMID 31099784) — EDR binds histone H1.3; proposed Fkbp1b transcriptional activation route.
- Kraskovskaya, Kukanova, Linkova, Popugaeva, Khavinson 2017 Bulletin of Experimental Biology and Medicine (DOI 10.1007/s10517-017-3847-2) — in primary mouse hippocampal neuron culture under amyloid-β synaptotoxicity (an Alzheimer’s-disease model in dish), EDR at 200 ng/mL increased mushroom-spine density by 71% and restored it to control levels. Mushroom spines are the dendritic-spine subtype where long-term memories are structurally encoded — a structural-rebuild finding, not just symptom suppression.
- Khavinson, Ilina, Kraskovskaya et al. 2021 Pharmaceuticals (Basel) 14(6):515 (PMID 34071923) — daily IP injection at 400 μg/kg for 2 months in 5xFAD-M mice (a severe transgenic Alzheimer’s model). KED (Vesugen) restored mushroom-spine number to control level (39.15% → 41.25%, p=0.003); EDR (Pinealon) increased mushroom spines by 25% in males specifically; partial LTP restoration was reported. Important caveats: (a) the peptides were tested SEPARATELY, not as a combination arm — the “Pinealon + Vesugen ≈ 100% normalization in 5XFAD” framing circulating in community-marketing content does not appear in the paper, (b) a 2025 correction notice (PMID 39861198) was issued because Figures 5 and 8 were identical but described differently — authors say the scientific conclusions are unaffected, but this is a real data-integrity flag that belongs alongside the citation.
- Meshchaninov, Tkachenko, Zharkov, Gavrilov, Katyreva 2015 Advances in Gerontology (PMID 26390612) — 32 patients (18 men / 12 women, aged 41-83) with chronic polymorbidity + organic brain syndrome in remission; Pinealon and Vesugen each had a “significant anabolic effect” and “slowed the rate of aging by biological-age indicators” measured via CD34+ hematopoietic stem cells, chromatin condensation, and chemiluminescence. Vesugen produced a more visible geroprophylactic effect than Pinealon in this cohort. The specific “-3.9 years (middle-aged) / -12.8 years (elderly)” figures circulating in community-marketing content do not appear in the published abstract, and a comparator labeled “Age Bot” does not exist in any indexed Pinealon literature — treat those specifics as (likely downstream marketing extrapolation); the underlying study is small, single-site, unblinded, n=32, peptides tested separately.
- Athletic-performance signal — elite gymnasts on a Pinealon + Kristagen stack. Khavinson-group work via Lesgaft National State University of Physical Culture (St. Petersburg; not PubMed-indexed): 20 elite Russian rhythmic gymnasts (12 received the Pinealon + Kristagen combination for 20 days vs. 8 controls). Morning recovery heart rate fell from 83.8 to 74.2 BPM (~-9.6 BPM) while training-level and energy-provision scores rose. Some peptide-community sources reframe this as “Pinealon alone reduces resting HR 10-12 BPM in trained athletes” — that reframing strips both the Kristagen co-administration AND the elite-gymnast specificity, so present the finding with both caveats attached. The much-cited “+254% treadmill time vs. bemithyl in 10 days” and “+200% anti-hypoxia survival vs. Epitalon” numbers also circulate widely in vendor marketing but could not be anchored to a verifiable primary source as of June 2026 — directionally consistent with the Khavinson-group rat hypoxia line (Kozina, Arutjunyan, Khavinson 2008 Doklady Akademii Nauk, “Pinealon was the most efficient protective preparation ensuring the best rate of adaptation to hypoxia”) but the specific percentages appear to be citation-laundering through marketing copy. Tag those numbers or omit until the primary paper is pinned.
0035 categorization pass grade: C/green (cognitive cluster).
Real-world protocol
The doses and schedules here are for educational and informational purposes only. These peptides are sold for research use only and are not FDA-approved drugs. This is not medical advice. Consult a qualified physician before beginning any protocol.
Both oral and injectable are validated within the Khavinson protocols — Pinealon’s oral viability is genuinely unusual for a peptide and is one of its main practical features.
| Route | Dose | Cycle | Frequency |
|---|---|---|---|
| Oral | 20 mg/day (typically 2× 10 mg capsules), morning, empty stomach | 20-30 consecutive days | 2-3 cycles/year |
| Subcutaneous | 5-10 mg/day; rotate injection sites | 10-20 consecutive days | 2-3 cycles/year |
Dosing-source discrepancy to flag. A separate practitioner camp running Pinealon clinically describes the standard starting dose as ~200 mcg/day = 2 capsules of a 100-mcg formulation, with a brain-repair range up to ~900 mcg/day (9 capsules, divided 3×3), an injectable range of 0.01-0.1 mg/kg/day (the dose used in TBI patients per the Pinealon patent, ≈ 0.7-7 mg/day for a 70 kg adult), and an intranasal range matching the injectable. That’s two orders of magnitude below the 20 mg/day oral figure in the table above. The most likely reconciliation: the 20 mg figure tracks a different oral formulation (likely a higher-strength Russian retail capsule), while the 200-900 mcg figure tracks a lower-strength capsule format. OHM’s editorial position pending resolution: start at the low end of the lower range (~200 mcg/day) and titrate up only if needed, NOT default to the 20 mg figure — the lower starting dose is consistent with the dose range used in the published 5XFAD mouse study (400 μg/kg ≈ 28 mg for a 70 kg human, but injected IP not oral) and avoids the upper-range lethargy risk below. — the 100-mcg vs. 10-mg capsule formulation distinction needs pinning to a specific product.
Upper-range caveat: dosing near the upper end of the range (whichever scale you’re working in) can induce lethargy / drowsiness in some users. Stay in the lower-to-mid part of the range; only push toward the upper bound for a defined brain-repair use case with prior tolerance established.
Persistence claim: the Khavinson framework claims benefits continue 2-3 months post-cycle — the “epigenetic-like persistence” asserted for all Khavinson bioregulators (the basis for the cycle/rest pattern rather than continuous dosing) magnitude + duration in independent studies.
A surprising real-world signal — Pinealon for SLEEP (not its primary positioning)
Three independent practitioner-camp n=1 reports now converge on Pinealon improving sleep quality — none of them came from sources positioning Pinealon as a sleep compound, which strengthens the signal that it’s a real secondary effect rather than expectation bias.
- Humiston (2026-06-16, head-to-head self-test). A fitness creator tested three peptides head-to-head for sleep effects — DSIP (positioned as a sleep peptide; null for him), Epithalon (positioned partly on nocturnal-melatonin upregulation; null for him on sleep), and Pinealon (positioned as a neuroprotective antioxidant, not primarily as a sleep peptide). Pinealon was the surprise winner — he woke feeling almost rested despite a baseline of self-reported sleep apnea, light-sleeper sensitivity, and a noisy bedroom environment. The degraded baseline strengthens the signal.
- Norwitz (2026-06-24, oral Pinealon, second independent n=1). A Harvard-MD/Oxford-PhD-credentialed source, a self-described historically-poor sleeper, reported the most restorative sleep in a year+ after starting oral Pinealon, woke with notably elevated morning energy, and reported a distinctive REM-vivid dream phenomenon. Now uses Pinealon combined with Epitalon as a “Russian longevity stack” for circadian rhythm + brain function, with sleep remaining materially better since starting the combo.
- Huberman Lab / Koniver episode (2024-10-07, third independent n=1). On that podcast episode (segment ~01:24:47), Andrew Huberman reported that Pinealon (combined with oral glycine 3-5 g, pulsed not nightly) approximately doubled his self-tracked REM sleep over 4-6 months — from roughly 1-1.5 hours per night to roughly 3 hours per night — framing it as the first sleep tool he’d found that meaningfully moved REM sleep upward.
Honest framing: three n=1 anecdotes from three different credentialed sources are not a sleep trial — they do NOT establish Pinealon as a sleep peptide in any clinical-evidence sense. But the convergence pattern is worth weighing: all three users came at it from non-sleep-positioned contexts, baselines varied, and the mechanism plausibly supports the observation as a secondary effect (antioxidant + serotonergic-modulation → cortical calming + oxidative-stress reduction during sleep + dream-architecture changes consistent with REM expansion). The Huberman combination with oral glycine 3-5 g is a specific protocol detail worth knowing for anyone trialing the same approach. Cross-link to DSIP (the “intuitive” sleep peptide that didn’t help one tested user) and Epithalon (Norwitz pairs the two as a longevity stack).
Side effects & management
- Mild and uncommon: Headache (early days), sleep disturbance with evening dosing (dose AM only), mild GI upset on the oral route, injection-site reactions.
- No serious AEs reported in published Russian research across a decade+ — but this is Russian-source pharmacovigilance only; long-term Western safety data doesn’t exist.
- Contraindications cited in the Russian protocols: Pregnancy, breastfeeding, age <18, active seizure disorders, concurrent serotonergic medications (SSRIs, etc.).
- Counterfeiting risk is significant for this category specifically — a verified-COA vendor matters more for Khavinson-family peptides than for most others because Russian-source counterfeit product is the dominant gray-market failure mode.
Regulatory status
Not FDA-approved. Long clinical-use history in Russia under Khavinson-school protocols; no Western RCTs.
Where to buy. Pinealon is not in Alyve’s current launch catalog, but it is available through BioLongevity — use code OHM-15 (BioLongevity shares Alyve’s coupon code) for 15% off. Given the counterfeiting risk flagged above, a third-party-COA, identity-confirmed product matters disproportionately for this peptide.
Technical & analytical reference (chemistry & QC)
| Field | Value |
|---|---|
| Molecular formula | C15H26N6O8 |
| Average MW | 418.40 g/mol (the body-text figure of 418.41 is consistent, rounding) — some vendor sources give 402.4 or 432.43, both wrong |
| CAS | none established |
| Sequence | Glu-Asp-Arg (EDR) |
| PubChem CID | 10273502 |
Sources
- primary source for mechanism claims, dosing protocols, and the Khavinson framework context.
- baseline grading (C/green ).
- Nick Norwitz MD PhD explainer on Khavinson/Epitalon/Pinealon for sleep and longevity; source of the Norwitz n=1 anecdote and the verified reference to Andrew Huberman’s Oct 7, 2024 Huberman Lab Koniver episode (verified via the official episode page + multiple secondary recaps converging on the Pinealon-specific attribution at segment timestamp 01:24:47); also source of the Pinealon + Epitalon “Russian longevity stack” combo framing. Norwitz’s vendor-affiliate and “biological age under 18” framing were flagged as practitioner-bias / marketing flourish and NOT propagated here.
- source of the FKBP1B “master regulator” framing (verified to be a stitching of Khavinson 2019 mechanism paper + Gant 2018 viral-vector validator), the Pinealon-name-myth correction, the dosing-source discrepancy (200-900 mcg/day clinical vs 20 mg/day in the table), the upper-range lethargy caveat, and the primary-literature pointers verified in that pass (Kraskovskaya 2017 mushroom-spine rescue; Khavinson/Ilina 2021 5XFAD mice + 2025 correction notice; Meshchaninov 2015 biological-age cohort; Khavinson/Linkova/Tarnovskaya 2019 EDR-histone-H1.3 mechanism; Lesgaft gymnasts study — not PubMed-indexed). The “+254% treadmill vs bemithyl”, “+200% anti-hypoxia vs Epitalon”, “-3.9 yrs/-12.8 yrs”, the “Age Bot” comparator, and the “Pinealon+Vesugen = 100% normalization in 5XFAD” framings were all flagged as community-marketing extrapolations not anchored to primary literature and are NOT used as wiki claims.
- Migrated from
cognitive-peptides-cluster.md(retired) — 2026-07-16.
Related: Cortagen · Dihexa · Epithalon · Semax · Selank · DSIP · the Khavinson bioregulator family.
Sources & references
- primary source for mechanism claims, dosing protocols, and the Khavinson framework context.
- baseline grading (C/green ).
- Nick Norwitz MD PhD explainer on Khavinson/Epitalon/Pinealon for sleep and longevity; source of the Norwitz n=1 anecdote and the verified reference to Andrew Huberman’s Oct 7, 2024 Huberman Lab Koniver episode (verified via the official episode page + multiple secondary recaps converging on the Pinealon-specific attribution at segment timestamp 01:24:47); also source of the Pinealon + Epitalon “Russian longevity stack” combo framing. Norwitz’s vendor-affiliate and “biological age under 18” framing were flagged as practitioner-bias / marketing flourish and NOT propagated here.
- source of the FKBP1B “master regulator” framing (verified to be a stitching of Khavinson 2019 mechanism paper + Gant 2018 viral-vector validator), the Pinealon-name-myth correction, the dosing-source discrepancy (200-900 mcg/day clinical vs 20 mg/day in the table), the upper-range lethargy caveat, and the primary-literature pointers verified in that pass (Kraskovskaya 2017 mushroom-spine rescue; Khavinson/Ilina 2021 5XFAD mice + 2025 correction notice; Meshchaninov 2015 biological-age cohort; Khavinson/Linkova/Tarnovskaya 2019 EDR-histone-H1.3 mechanism; Lesgaft gymnasts study — not PubMed-indexed). The “+254% treadmill vs bemithyl”, “+200% anti-hypoxia vs Epitalon”, “-3.9 yrs/-12.8 yrs”, the “Age Bot” comparator, and the “Pinealon+Vesugen = 100% normalization in 5XFAD” framings were all flagged as community-marketing extrapolations not anchored to primary literature and are NOT used as wiki claims.
- Migrated from
cognitive-peptides-cluster.md(retired) — 2026-07-16.
Related: Cortagen · Dihexa · Epithalon · Semax · Selank · DSIP · the Khavinson bioregulator family.